芪灯明目胶囊对自发性糖尿病大鼠视网膜蛋白激酶C及玻璃体血管内皮生长因子影响的实验研究
|
摘要
目的:观察芪灯明目胶囊对自发性糖尿病大鼠视网膜蛋白激酶C及玻璃体血管内皮生长因子的影响,探讨中医药治疗糖尿病视网膜病变的机制。
方法:从形态学等方面对自发性糖尿病大鼠模型进行评价。并采用6个月病程的自发性糖尿病大鼠模型,随机分为6组:阴性对照组、芪灯明目胶囊低、中、高剂量组、递法明组及导升明组,另设有正常对照组。连续灌胃3个月,并于灌胃3月末处死大鼠,通过酶联免疫及免疫组化等方法,观察芪灯明目胶囊对自发性糖尿病大鼠视网膜蛋白激酶C及玻璃体血管内皮生长因子的影响。
结果:(1)自发性糖尿病大鼠(GK大鼠)可以作为人类糖尿病视网膜病变背景期病理改变的模型,特别是Ⅱ型糖尿病动物模型。(2)芪灯明目胶囊有改善自发性糖尿病大鼠生存状态的作用。(3)芪灯明目胶囊具有抑制自发性糖尿病大鼠视网膜蛋白激酶C活化的作用。(4)芪灯明目胶囊可以降低自发性糖尿病大鼠玻璃体血管内皮生长因子的水平,从而对新生血管的形成起到抑制作用。(5)芪灯明目胶囊对自发性糖尿病大鼠血糖有一定降低作用。
结论:自发性糖尿病大鼠(GK大鼠)可以作为人类糖尿病视网膜病变背景期病理改变的模型,特别是Ⅱ型糖尿病动物模型。芪灯明目胶囊具有抑制自发性糖尿病大鼠视网膜蛋白激酶C活化的作用,降低自发性糖尿病大鼠玻璃体血管内皮生长因子的水平,对糖尿病视网膜组织有一定的保护作用,对新生血管形成有抑制作用。
Objective: To observe the effect of QiDengMingMu capsule on protein kinase C in retinas and the Vascular endothelial growth factor in vitreous of the experimental animal model of spontaneous diabetic retinopathy rats (Goto-kakizaki rats), and to explore the pathological mechanism of Chinese Medicine on diabetic retinopiathy (DR) .
Methods: To evaluate the experimental animal model of spontaneous diabetic retinopathy rats (Goto-kakizaki rat) in morphology. The GK rats with six month course are randomly divided into 6 groups according to the weight and the level of blood glucose:model control group, treated groups with high、middle、low dosage of QiDengMingMu capsule , positive control group of Difral and Doxium, and normal control group, respectively. After given drugs or distilled water for 3 months, the rats were put to death and eyeballs of the rats are taken out. Their vitreous and retinas were studied by means of enzyme linked immunosorbent assay (ELISA) and immunohistochemistry respectively.
Results:(1)The experimental animal model of spontaneous diabetic retinopathy rats may represet background stage of diabetic retinopathy in human, especially the experimental animal model of non-insulin dependent diabetic retinopathy. (2)The Chinese medicine QiDengMingMu capsule has the effect of improving the quality of life of the GK rats. (3)The Chinese medicine QiDengMingMu capsule can inhibit the activity of PKC of the GK rats in retinas. (4)The Chinese medicine QiDengMingMu capsule can reduce the level of the Vascular endothelial growth facter of the GK rats in vitreous. (5)The decrease in the blood glucose level of the GK rats is partly owing to the Chinese medicine QiDengMingMu capsule.
Conclusion:The experimental animal model of spontaneous diabetic retinopathy rats may represet background stage of diabetic retinopathy in human, especially the experimental animal model of non-insulin dependent diabetic retinopathy. The Chinese medicine QiDengMingMu capsule can the inhibit activity of PKC of the GK rats in retinas and can reduce the level of the Vascular endothelial growth facter of the GK rats in vitreous. So it is a good capillary protective agent to the GK rats'retinal impairment and it can cure the damage of retinas in the GK rats.
方法:从形态学等方面对自发性糖尿病大鼠模型进行评价。并采用6个月病程的自发性糖尿病大鼠模型,随机分为6组:阴性对照组、芪灯明目胶囊低、中、高剂量组、递法明组及导升明组,另设有正常对照组。连续灌胃3个月,并于灌胃3月末处死大鼠,通过酶联免疫及免疫组化等方法,观察芪灯明目胶囊对自发性糖尿病大鼠视网膜蛋白激酶C及玻璃体血管内皮生长因子的影响。
结果:(1)自发性糖尿病大鼠(GK大鼠)可以作为人类糖尿病视网膜病变背景期病理改变的模型,特别是Ⅱ型糖尿病动物模型。(2)芪灯明目胶囊有改善自发性糖尿病大鼠生存状态的作用。(3)芪灯明目胶囊具有抑制自发性糖尿病大鼠视网膜蛋白激酶C活化的作用。(4)芪灯明目胶囊可以降低自发性糖尿病大鼠玻璃体血管内皮生长因子的水平,从而对新生血管的形成起到抑制作用。(5)芪灯明目胶囊对自发性糖尿病大鼠血糖有一定降低作用。
结论:自发性糖尿病大鼠(GK大鼠)可以作为人类糖尿病视网膜病变背景期病理改变的模型,特别是Ⅱ型糖尿病动物模型。芪灯明目胶囊具有抑制自发性糖尿病大鼠视网膜蛋白激酶C活化的作用,降低自发性糖尿病大鼠玻璃体血管内皮生长因子的水平,对糖尿病视网膜组织有一定的保护作用,对新生血管形成有抑制作用。
Objective: To observe the effect of QiDengMingMu capsule on protein kinase C in retinas and the Vascular endothelial growth factor in vitreous of the experimental animal model of spontaneous diabetic retinopathy rats (Goto-kakizaki rats), and to explore the pathological mechanism of Chinese Medicine on diabetic retinopiathy (DR) .
Methods: To evaluate the experimental animal model of spontaneous diabetic retinopathy rats (Goto-kakizaki rat) in morphology. The GK rats with six month course are randomly divided into 6 groups according to the weight and the level of blood glucose:model control group, treated groups with high、middle、low dosage of QiDengMingMu capsule , positive control group of Difral and Doxium, and normal control group, respectively. After given drugs or distilled water for 3 months, the rats were put to death and eyeballs of the rats are taken out. Their vitreous and retinas were studied by means of enzyme linked immunosorbent assay (ELISA) and immunohistochemistry respectively.
Results:(1)The experimental animal model of spontaneous diabetic retinopathy rats may represet background stage of diabetic retinopathy in human, especially the experimental animal model of non-insulin dependent diabetic retinopathy. (2)The Chinese medicine QiDengMingMu capsule has the effect of improving the quality of life of the GK rats. (3)The Chinese medicine QiDengMingMu capsule can inhibit the activity of PKC of the GK rats in retinas. (4)The Chinese medicine QiDengMingMu capsule can reduce the level of the Vascular endothelial growth facter of the GK rats in vitreous. (5)The decrease in the blood glucose level of the GK rats is partly owing to the Chinese medicine QiDengMingMu capsule.
Conclusion:The experimental animal model of spontaneous diabetic retinopathy rats may represet background stage of diabetic retinopathy in human, especially the experimental animal model of non-insulin dependent diabetic retinopathy. The Chinese medicine QiDengMingMu capsule can the inhibit activity of PKC of the GK rats in retinas and can reduce the level of the Vascular endothelial growth facter of the GK rats in vitreous. So it is a good capillary protective agent to the GK rats'retinal impairment and it can cure the damage of retinas in the GK rats.
引文
1 Martin Silink.Unite for diabetes.The campaign for a UN Resolution.DiabetesVoice,2006,June,51(2):27-30
2 Sarah Wild,Gojka Roglic,Anders Green,etc.Global Prevalence of Diabetes.DIABETES CARE,2004,MAY,27(5):1047-1053
3 Rathmann W,Giani G.Estimates for the year 2000 and projections for 2030.Diabetes Care,2004,27(10):2568-2569
4 李秀钧.糖尿病研究进展-第16届国际糖尿病联盟大会纪要.中国内分泌杂志,1998,14(2):34
5 卫生部疾病控制司,中华医学会糖尿病学分会.中国糖尿病防治指南,第一版.北京:北京大学医学出版社,2004,10
6 孙河,滕晓明,李雪莹.糖尿病视网膜病变的研究概况.中医药信,2004,4(21)
7 张斌,向红丁,毛微波,等.北京、上海、天津、重庆四城市住院2型糖尿病患者糖尿病慢性并发症及相关大血管疾病的流行病学分析.中国医学科学院学报,2002,24(5):452-456
8 钱荣立,潘长玉,童光焕,朱禧星,等.糖尿病临床指南.北京:北京医科大学出版社,2000,186-197
9 段俊国主编.中西医结合眼科学.北京:中国中医药出版社,2005,260
10 池芝盛.为加强糖尿病防治及研究而努力.中华内分泌代谢杂志,1992,8(2):67
11 Diabetes:the cost of diabetes.http://www.who.int/mediacentre/factsheets/fs236/en/print.html
12 张承芬,张惠蓉主编.糖尿病眼部并发症.北京:人民卫生出版社,2004,21
13 史育慧,雷嘉启.非胰岛素依赖型糖尿病中糖尿病视网膜病的诊断和相关危险因素.美国医学会眼科杂志中文版,1999,11(1):23-29
14 Eva,M.Kohner,etal.非胰岛素依赖型糖尿病中糖尿病视网膜病变的诊断与相关危险因素.美国医学会眼科杂志中文版,1999,11(1):23-29
15 郑霖.胰岛素依赖型糖尿病视网膜病变的发病率及其相关危险因素.美国医学会眼科杂志中文版,1998,10(1):12-17
16 罗成仁.亟待开展和深入的糖尿病视网膜病变研究.中华眼底病杂志,1995,11(4):215
17 许爱梅,庄向华,周建博,等.糖尿病视网膜病变研究进展.国外医学内科学分册,2004,31(2):47-49
18 Lawrence J.Current hypotheses for the biochenmical basis of diabetic retinopathy.Diabetes Care,1992,15(12),1892
19 M asakazu M et al.The effect of high glucose and aldose reductase inhibitor(FK366) on myoinositol up take in cultured bovine pericyte.Diabetes,1998,47(supp 11):A 379
20 Gilbert RE,et al.Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.Lab Invest,1998,78(8):1017
21 Roufail E,et al.Depletion of nitric oxide synthase-containing neuron in the diabetic retina reversal by aminoguanidine.Diabetologia,1998,44(12):141
22 Honda M,et al.Alteration of GABA ergic neurinal system of the retina and superior colliculus in streptozotocin-induced diabetic rat.Kobe J Med Sci,1998,44(1):1-8
23 Smith LE,Shen W,Perruzzi C,et al.Regulationof vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.Nat Med,1999,5:1390-1395
24 Smith LEH,Kopchick JJ,Chen W,et al.Essential role of growth hormone in ischemia induced retinal neovascularization.Science1997;276:1706-9
25 N Engl J Med.The Diabetes Control and Complications Trial Research Group.Diabetes,1997,46(11):1829-1839.
26 AsthtonN.Vascul arbasement membrane change sindiabeti cretinopathy [J].Ophthalmol,1974,58(3):344
27 WiedemannP.Growth factor sinretinal diaeses:proliferative vitreo retinopathy,proliferative diabetic-retinophathy and retinal degeneration[J].Surv Ophthalmol,1992,36(5):373
28 LiW,YanoffM,LiuX.Pericyte apoptosisin early diabetic retinopathy [J].Invest Ophthalmol VesSci,1997,38(4):769
29 王光路,卢宁,张凤,等.二极管激光在眼底病中的应用[J].中华眼科杂志,1998,34(1):45-46
30 黄建纲.糖尿病性视网膜病变的光凝治疗[J].国外医学·眼科分册,1994,6(18):358-363
31 陈通文.糖尿病论治的临床研究进展[J].中国中医药信息杂志,2000,(1):18
32 李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[J].国医论坛,2000,(6):24
33 李红,夏建生.糖尿病视网膜病变辨证有分型的临床研究[J].河南中医,2000,(5):33
34 叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005,144-146
35 刘静.中药治疗糖尿病慢性并发症的经验.中医杂志,1994,35(1):38
36 吕仁和主编.糖尿病(消渴病)中医诊治荟萃.北京:中国医药科技出版社,1999,129-131
37 吕仁和主编.消渴病研究生参考教材.内部资料,1997,22-25
38 廖品正.糖尿病中医诊治荟萃.北京:中国医药科技出版社,1999,427
39 谢学军,王明芳.糖尿病视网膜病变病机探讨[J].中国中医眼科杂志,1995(5):86-88
40 张福君.中医辨证糖尿病回归与进展[J].辽宁中医杂志,1992,9:45
41 李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨[J].广州中医药大学学报,1999,16(4):275
42 宋前方,李晓星.血塞通注射液治疗糖尿病性视网膜病变.佳木斯医学院学报,1997,20(4):31
43 李晓星,程晓霞,高玉新,等.血塞通注射液治疗糖尿病性视网膜病变.河南中医,2001,21(3):54
44 柯晓云,吴艺.丹参对糖尿病视网膜病变患者脂质过氧化物及超氧化物歧化酶的影响.中国中医眼科杂志,1997,7(4):205
45 刘俊瑛,郝洪钟,李焱.红花静点注射对糖尿病性视网膜病变的影响.山西医药杂志,1995,24(4):234
46 窦敬芳,翁孝刚.川芎嗪治疗糖尿病性视网膜病变临床研究.眼科新进展,1998,18(3):138
47 何剑峰,周伟平,仇宜解,等.枸杞对糖尿病视网膜病变患者抗氧化反应作用的临床研究.中国中医眼科杂志,1998,8(2):74
48 何剑峰,周伟平,仇宜解.糖尿病视网膜病变患者红细胞免疫功能的变化及枸杞的治疗效应.中国中医眼科杂志,1998,8(2):70
49 任平,胡惠君,张瑞.葛根素治疗糖尿病视网膜病变的疗效观察.中国中西医结合杂志,2000,20(8):574
50 姚敏,郑军.中医对糖尿病视网膜病变认识的现状.中医药学报2003,31(3):59-60
51 相莉,吴谊青,刘新玲.络泰治疗糖尿病视网膜病变.中草药,2000,31(4):50
52 张富文.中药部位复方芪灯明目胶囊对STZ诱发糖尿病大鼠血视网膜屏障和视功能影响的实验研究.2005年博士学位论文,5-6
53 李瑞全等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠视网膜超微结构的影响.中国中医眼科杂志,1996,6(2):62
54 谢学军等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠视神经组织形态的影响.中国中医眼科杂志,1996,6(3):131
55 廖品正等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠周细胞的保护作 用,1994,25:27
56 叶河江.中药复方优糖明治疗糖尿病性视网膜病变的实验研究.1999年博士学位论文,50
57 廖蓉,谭毅,王鸿雏.糖尿病研究与动物模型.实验动物科学与管理,2001,18(2)
58 张惠荣主编.眼微循环及相关眼病.北京:北京医科大学、中国协和医科大学联合出版,1993,19-21
59 Kador PF,Takahashi Y,Wyman M,et,al.Diabeteslike proliferative proliferative retinal changes in goloctose-fed dogs[J].Arch Ophthalmol,1984,102(4):520-526
60 宋鄂,董宇,石博,赵生友,吴家祥.STZ糖尿病大鼠视网膜病变模型的评价.眼科研究,2004,4,(22.2):124-127
61 李才锐,姜德咏.糖尿病视网膜病变动物模型.国外医学眼科学分册,2005,2(29,1):(44-48)
62 王宝金,代解杰.糖尿病动物模型的研究进展.上海实验动物科学,2003,3(2):116-118
63 王宝金,代解杰.糖尿病动物模型的研究进展.上海实验动物科学,2003,23(2):116-118
64 Miyamoto K,Ogura Y,Nishiwaki H.A spontaneous model of non-insulin-dependent diabetes.Invest Ophthalmol Vis Sci,1996,37:898-905
65 Takeo-Goto S,Doi M,Ma N,et al.lmmunohistochemical localization of amino acids In the diabetic retina of Goto-Kakizaki rats.Ophthalmic Res,2002,4:139-145
66 Sone H,Kawakami Y,Okuda Y,Sekine Y,Honmura S,Matsuo K,Segawa T,Suzuki H,Yamashita K.cular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes.Diabetologia,1997 Jun,40(6):26-30
67 Tamim Q,Qingwen X,Antonia M,et al.VEGF-initiated Blood-Retinal Barrier Breakdown in Early Diabetes[J]. Invest Ophthalraol Vis Sci,2001,42(10):2408-2413
68 Wu Y, Zhang Q, Ann DK. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts[ J ].Am J Physiol Cell,2004, 286(4): 905-912
69 Joussen AM, Poulaki V, Qin W, et al. Retinal Vascular Endothelial Growth Factor Induces Intercellular Adhesion Molecule-1 and Endothelial Nitric Oxide Synthase Expression and Initiates Early Diabetic Retinal Leukocyte Adhesion in Vivo [ J ]. Am J Pathol, 2002,160 (2):501-509
70 Goodsell DS. The Molecular Perspective: VEGF and angiogenesis[J]. Oncologist, 2002,7 (6): 569-570
71 Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor- induced retinal permeability is mediated by protein kinase in vivo ang suppressedby an orally effective-isoform-selective inhibitor[ J].Diabetes, 1997,46(9): 1473-1480
72 Lukiw WJ, Ottlecz A, Lambrou G, et al. Coordinate activation of HIF-land NF- κ B DNA Binding and COX-2 and VEGF Expression in Retinal Cells by Hypoxia[J]. Invest Ophthalmol Vis Sci, 2003,44 (10):4163-4170
73 Xiao W, Vinores SA, Shen J, et al. Ischemia Induces Blood-retinal Barrier (BRB) Breakdown through HIF-1 Dependent VEGF Upregulation and VEGF Mediates BRB Breakdown through ICAM-1 and Adenosine [J].Invest Ophthalmol Vis Sci ,2003,44(5):3209
74 Levy AP, Pages G, Berra E, et al. Stress-activated Protein Kinases (JNK and p38/H0G) Are Essential for Vascular Endothelial Growth Factor mRNA Stability [J]. J Biol Chem, 2000, 275 ( 34 ) : 26484-26491
75 RemaM,PonnaiyaM,MohanV.Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India.Diabetes Res Clin Pract,1996,34(1):29-36
76 RemaM,Deepar,MobanV.Prevalence of retinopathy at diagnosis among type 2 diabetic patients attending a diabetic centre in South India.Br JO phthalmoi,2000,84(9):1058-1060
77 高彦彬.国内外中医药治疗糖尿病最新进展.中国中医药信息杂志,1995,2(2):24
2 Sarah Wild,Gojka Roglic,Anders Green,etc.Global Prevalence of Diabetes.DIABETES CARE,2004,MAY,27(5):1047-1053
3 Rathmann W,Giani G.Estimates for the year 2000 and projections for 2030.Diabetes Care,2004,27(10):2568-2569
4 李秀钧.糖尿病研究进展-第16届国际糖尿病联盟大会纪要.中国内分泌杂志,1998,14(2):34
5 卫生部疾病控制司,中华医学会糖尿病学分会.中国糖尿病防治指南,第一版.北京:北京大学医学出版社,2004,10
6 孙河,滕晓明,李雪莹.糖尿病视网膜病变的研究概况.中医药信,2004,4(21)
7 张斌,向红丁,毛微波,等.北京、上海、天津、重庆四城市住院2型糖尿病患者糖尿病慢性并发症及相关大血管疾病的流行病学分析.中国医学科学院学报,2002,24(5):452-456
8 钱荣立,潘长玉,童光焕,朱禧星,等.糖尿病临床指南.北京:北京医科大学出版社,2000,186-197
9 段俊国主编.中西医结合眼科学.北京:中国中医药出版社,2005,260
10 池芝盛.为加强糖尿病防治及研究而努力.中华内分泌代谢杂志,1992,8(2):67
11 Diabetes:the cost of diabetes.http://www.who.int/mediacentre/factsheets/fs236/en/print.html
12 张承芬,张惠蓉主编.糖尿病眼部并发症.北京:人民卫生出版社,2004,21
13 史育慧,雷嘉启.非胰岛素依赖型糖尿病中糖尿病视网膜病的诊断和相关危险因素.美国医学会眼科杂志中文版,1999,11(1):23-29
14 Eva,M.Kohner,etal.非胰岛素依赖型糖尿病中糖尿病视网膜病变的诊断与相关危险因素.美国医学会眼科杂志中文版,1999,11(1):23-29
15 郑霖.胰岛素依赖型糖尿病视网膜病变的发病率及其相关危险因素.美国医学会眼科杂志中文版,1998,10(1):12-17
16 罗成仁.亟待开展和深入的糖尿病视网膜病变研究.中华眼底病杂志,1995,11(4):215
17 许爱梅,庄向华,周建博,等.糖尿病视网膜病变研究进展.国外医学内科学分册,2004,31(2):47-49
18 Lawrence J.Current hypotheses for the biochenmical basis of diabetic retinopathy.Diabetes Care,1992,15(12),1892
19 M asakazu M et al.The effect of high glucose and aldose reductase inhibitor(FK366) on myoinositol up take in cultured bovine pericyte.Diabetes,1998,47(supp 11):A 379
20 Gilbert RE,et al.Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.Lab Invest,1998,78(8):1017
21 Roufail E,et al.Depletion of nitric oxide synthase-containing neuron in the diabetic retina reversal by aminoguanidine.Diabetologia,1998,44(12):141
22 Honda M,et al.Alteration of GABA ergic neurinal system of the retina and superior colliculus in streptozotocin-induced diabetic rat.Kobe J Med Sci,1998,44(1):1-8
23 Smith LE,Shen W,Perruzzi C,et al.Regulationof vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.Nat Med,1999,5:1390-1395
24 Smith LEH,Kopchick JJ,Chen W,et al.Essential role of growth hormone in ischemia induced retinal neovascularization.Science1997;276:1706-9
25 N Engl J Med.The Diabetes Control and Complications Trial Research Group.Diabetes,1997,46(11):1829-1839.
26 AsthtonN.Vascul arbasement membrane change sindiabeti cretinopathy [J].Ophthalmol,1974,58(3):344
27 WiedemannP.Growth factor sinretinal diaeses:proliferative vitreo retinopathy,proliferative diabetic-retinophathy and retinal degeneration[J].Surv Ophthalmol,1992,36(5):373
28 LiW,YanoffM,LiuX.Pericyte apoptosisin early diabetic retinopathy [J].Invest Ophthalmol VesSci,1997,38(4):769
29 王光路,卢宁,张凤,等.二极管激光在眼底病中的应用[J].中华眼科杂志,1998,34(1):45-46
30 黄建纲.糖尿病性视网膜病变的光凝治疗[J].国外医学·眼科分册,1994,6(18):358-363
31 陈通文.糖尿病论治的临床研究进展[J].中国中医药信息杂志,2000,(1):18
32 李劲亮.消渴明目方治疗早期糖尿病性视网膜病变35例[J].国医论坛,2000,(6):24
33 李红,夏建生.糖尿病视网膜病变辨证有分型的临床研究[J].河南中医,2000,(5):33
34 叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005,144-146
35 刘静.中药治疗糖尿病慢性并发症的经验.中医杂志,1994,35(1):38
36 吕仁和主编.糖尿病(消渴病)中医诊治荟萃.北京:中国医药科技出版社,1999,129-131
37 吕仁和主编.消渴病研究生参考教材.内部资料,1997,22-25
38 廖品正.糖尿病中医诊治荟萃.北京:中国医药科技出版社,1999,427
39 谢学军,王明芳.糖尿病视网膜病变病机探讨[J].中国中医眼科杂志,1995(5):86-88
40 张福君.中医辨证糖尿病回归与进展[J].辽宁中医杂志,1992,9:45
41 李志英,余杨桂,张淳,等.糖尿病视网膜病变与血瘀关系的探讨[J].广州中医药大学学报,1999,16(4):275
42 宋前方,李晓星.血塞通注射液治疗糖尿病性视网膜病变.佳木斯医学院学报,1997,20(4):31
43 李晓星,程晓霞,高玉新,等.血塞通注射液治疗糖尿病性视网膜病变.河南中医,2001,21(3):54
44 柯晓云,吴艺.丹参对糖尿病视网膜病变患者脂质过氧化物及超氧化物歧化酶的影响.中国中医眼科杂志,1997,7(4):205
45 刘俊瑛,郝洪钟,李焱.红花静点注射对糖尿病性视网膜病变的影响.山西医药杂志,1995,24(4):234
46 窦敬芳,翁孝刚.川芎嗪治疗糖尿病性视网膜病变临床研究.眼科新进展,1998,18(3):138
47 何剑峰,周伟平,仇宜解,等.枸杞对糖尿病视网膜病变患者抗氧化反应作用的临床研究.中国中医眼科杂志,1998,8(2):74
48 何剑峰,周伟平,仇宜解.糖尿病视网膜病变患者红细胞免疫功能的变化及枸杞的治疗效应.中国中医眼科杂志,1998,8(2):70
49 任平,胡惠君,张瑞.葛根素治疗糖尿病视网膜病变的疗效观察.中国中西医结合杂志,2000,20(8):574
50 姚敏,郑军.中医对糖尿病视网膜病变认识的现状.中医药学报2003,31(3):59-60
51 相莉,吴谊青,刘新玲.络泰治疗糖尿病视网膜病变.中草药,2000,31(4):50
52 张富文.中药部位复方芪灯明目胶囊对STZ诱发糖尿病大鼠血视网膜屏障和视功能影响的实验研究.2005年博士学位论文,5-6
53 李瑞全等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠视网膜超微结构的影响.中国中医眼科杂志,1996,6(2):62
54 谢学军等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠视神经组织形态的影响.中国中医眼科杂志,1996,6(3):131
55 廖品正等.滋养肝肾、活血化瘀中药对实验性糖尿病大鼠周细胞的保护作 用,1994,25:27
56 叶河江.中药复方优糖明治疗糖尿病性视网膜病变的实验研究.1999年博士学位论文,50
57 廖蓉,谭毅,王鸿雏.糖尿病研究与动物模型.实验动物科学与管理,2001,18(2)
58 张惠荣主编.眼微循环及相关眼病.北京:北京医科大学、中国协和医科大学联合出版,1993,19-21
59 Kador PF,Takahashi Y,Wyman M,et,al.Diabeteslike proliferative proliferative retinal changes in goloctose-fed dogs[J].Arch Ophthalmol,1984,102(4):520-526
60 宋鄂,董宇,石博,赵生友,吴家祥.STZ糖尿病大鼠视网膜病变模型的评价.眼科研究,2004,4,(22.2):124-127
61 李才锐,姜德咏.糖尿病视网膜病变动物模型.国外医学眼科学分册,2005,2(29,1):(44-48)
62 王宝金,代解杰.糖尿病动物模型的研究进展.上海实验动物科学,2003,3(2):116-118
63 王宝金,代解杰.糖尿病动物模型的研究进展.上海实验动物科学,2003,23(2):116-118
64 Miyamoto K,Ogura Y,Nishiwaki H.A spontaneous model of non-insulin-dependent diabetes.Invest Ophthalmol Vis Sci,1996,37:898-905
65 Takeo-Goto S,Doi M,Ma N,et al.lmmunohistochemical localization of amino acids In the diabetic retina of Goto-Kakizaki rats.Ophthalmic Res,2002,4:139-145
66 Sone H,Kawakami Y,Okuda Y,Sekine Y,Honmura S,Matsuo K,Segawa T,Suzuki H,Yamashita K.cular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes.Diabetologia,1997 Jun,40(6):26-30
67 Tamim Q,Qingwen X,Antonia M,et al.VEGF-initiated Blood-Retinal Barrier Breakdown in Early Diabetes[J]. Invest Ophthalraol Vis Sci,2001,42(10):2408-2413
68 Wu Y, Zhang Q, Ann DK. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts[ J ].Am J Physiol Cell,2004, 286(4): 905-912
69 Joussen AM, Poulaki V, Qin W, et al. Retinal Vascular Endothelial Growth Factor Induces Intercellular Adhesion Molecule-1 and Endothelial Nitric Oxide Synthase Expression and Initiates Early Diabetic Retinal Leukocyte Adhesion in Vivo [ J ]. Am J Pathol, 2002,160 (2):501-509
70 Goodsell DS. The Molecular Perspective: VEGF and angiogenesis[J]. Oncologist, 2002,7 (6): 569-570
71 Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor- induced retinal permeability is mediated by protein kinase in vivo ang suppressedby an orally effective-isoform-selective inhibitor[ J].Diabetes, 1997,46(9): 1473-1480
72 Lukiw WJ, Ottlecz A, Lambrou G, et al. Coordinate activation of HIF-land NF- κ B DNA Binding and COX-2 and VEGF Expression in Retinal Cells by Hypoxia[J]. Invest Ophthalmol Vis Sci, 2003,44 (10):4163-4170
73 Xiao W, Vinores SA, Shen J, et al. Ischemia Induces Blood-retinal Barrier (BRB) Breakdown through HIF-1 Dependent VEGF Upregulation and VEGF Mediates BRB Breakdown through ICAM-1 and Adenosine [J].Invest Ophthalmol Vis Sci ,2003,44(5):3209
74 Levy AP, Pages G, Berra E, et al. Stress-activated Protein Kinases (JNK and p38/H0G) Are Essential for Vascular Endothelial Growth Factor mRNA Stability [J]. J Biol Chem, 2000, 275 ( 34 ) : 26484-26491
75 RemaM,PonnaiyaM,MohanV.Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India.Diabetes Res Clin Pract,1996,34(1):29-36
76 RemaM,Deepar,MobanV.Prevalence of retinopathy at diagnosis among type 2 diabetic patients attending a diabetic centre in South India.Br JO phthalmoi,2000,84(9):1058-1060
77 高彦彬.国内外中医药治疗糖尿病最新进展.中国中医药信息杂志,1995,2(2):24